Harnessing AI for Healthcare: A New Dawn for South Africa

By Sumona Bose

February 7, 2024

The Need for AI-Driven Healthcare Policy in South Africa

South Africa’s healthcare sector is on the brink of a transformative era, with artificial intelligence (AI) at its helm. However, the current policy frameworks are ill-equipped to foster innovation in this burgeoning field. Five key issues demand immediate attention: outdated legislation, data and algorithmic bias, workforce impact, liability dilemmas, and a dearth of AI system innovation. The establishment of a comprehensive national policy framework addressing these concerns is crucial for the safe, responsible, and regulated adoption of AI in healthcare.

The Innovation Gap: AI Patenting in South Africa

A closer look at the patenting activity within AI in South Africa reveals a stark reality. Despite the country being listed in over 9,000 AI patent applications between 2012 and 2021, only ten patents were filed from within South Africa. This disparity underscores the need for an enabling environment that promotes the development of complex cognitive and creative AI systems.

Public Sector Data: The Key to AI-Driven Healthcare

One of the significant hurdles to AI development in Africa is data availability and the costs associated with its acquisition. The National Digital Health Strategy for South Africa 2019 – 2024 identifies the development of a patient electronic health record as a key priority. This record system could provide a wealth of high-quality data to train AI systems, alleviating the significant investment and effort required to curate non-optimised data.

The concept of using public sector data to develop, train, and improve AI-enabled systems is not new. The Declaration of Cooperation on Artificial Intelligence, ratified by 25 European countries in 2018, saw member states agree to ensure better access to public sector data to fuel AI development.

However, access to sensitive health data raises privacy and security concerns. A robust legal framework or governance system is needed to encourage innovation while preserving patient privacy and security. A federated data system, where data do not leave the participating organisation but can be accessed by authorised individuals to train algorithms, could be the solution.

Conclusion

The establishment of a public sector data institution, alongside the proposed patient electronic record, could incentivise the development and deployment of AI for use in healthcare in South Africa. By providing developers with secure and safe access to health data, we can respect the rights to intellectual property and digital authenticity.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.